410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.

Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

IPO in May 2017 (NASDAQ: GTHX).

Developer of novel, small-molecule therapies for the treatment of cancer designed to address significant unmet needs in the treatment of cancer. The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs, a family of proteins that play an important role in the growth and proliferation of cells, enabling the medical industry to treat cancer.

IMMvention is developing novel, first-in-class therapies for treating hemolytic anemias.

Acquired by Target RWE in December 2020.

NoviSci is a healthcare IT and services company with the mission of facilitating learning from real-world data (RWD) and real-world evidence (RWE). The company was founded based on the research of Drs. Alan Brookhart and Steve Cole, renowned professors/experts in causal inference and epidemiology from The University of North Carolina at Chapel Hill.

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

StartStopMove, Inc. DBA WalletFi

Acquired by Constellation Digital Partners in August 2022.

WalletFi’s mobile technology allows users to easily identify and move recurring charges, subscriptions, and card-on-file (CoF) payments across cards in their digital wallet. Most importantly, WalletFi reduces customer churn for banks and financial institutions while also increasing Millennial engagement and reinforcing top-of-wallet status.

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.

Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

IPO in May 2017 (NASDAQ: GTHX).

Developer of novel, small-molecule therapies for the treatment of cancer designed to address significant unmet needs in the treatment of cancer. The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs, a family of proteins that play an important role in the growth and proliferation of cells, enabling the medical industry to treat cancer.

IMMvention is developing novel, first-in-class therapies for treating hemolytic anemias.

Acquired by Target RWE in December 2020.

NoviSci is a healthcare IT and services company with the mission of facilitating learning from real-world data (RWD) and real-world evidence (RWE). The company was founded based on the research of Drs. Alan Brookhart and Steve Cole, renowned professors/experts in causal inference and epidemiology from The University of North Carolina at Chapel Hill.

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

StartStopMove, Inc. DBA WalletFi

Acquired by Constellation Digital Partners in August 2022.

WalletFi’s mobile technology allows users to easily identify and move recurring charges, subscriptions, and card-on-file (CoF) payments across cards in their digital wallet. Most importantly, WalletFi reduces customer churn for banks and financial institutions while also increasing Millennial engagement and reinforcing top-of-wallet status.

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.

IPO in March 2022 (NASDAQ: ANTX)

AN2 Therapeutics (“AN2”) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives.

AN2 is a mission-driven company. We have a passion for improving global public health and a vision to accelerate development of novel medicines to treat serious infectious diseases and save lives worldwide.

Acquired by PerkinElmer (NYS: PKI) in March 2011.

Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. The company offers Ensemble for Life Science, an on-demand software platform, that blends social networking, collaboration, and refined scientific data mining to assist internal and external research communication and management. It provides Ensemble Electronic Lab Notebook that allows users to capture experimental data, results, and decision support needs for their organization medicinal chemistry, biologists, and bio-analytical departments; and Ensemble Toolkits, enabling users to integrate components utilized inside platform technology into their application or environment.

AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart. The system is being developed to simplify and improve management of patients requiring temporary pacing as well as those with a need for permanent pacing. Initial clinical feasibility has been demonstrated and the company is now well-positioned to develop the technology through pivotal studies and regulatory approval.

Atsena Therapeutics is a clinical-stage, ophthalmology-focused gene therapy company based on research from Dr. Shannon Boye’s lab at the University of Florida. 

Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs. It focuses on commercializing neuromodulation technology platforms designed to treat patients suffering from chronic diseases.

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University.

The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.

BEKHealth accelerates clinical research by providing EMR data processing, feasibility and site selection, precision patient matching and care coordination. Their clinical research software accelerates timelines by automating multiple high impact processes.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

Click the logo for information on Boomerang’s clinical trial

Boomerang Medical is developing a technology to advance the treatment of autoimmune diseases by using electrical nerve stimulation to manage inflammation and immune response.

Boston Immune Technologies and Therapeutics (BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases.

Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

IPO in June, 2016 (NASDAQ:CLSD).

Manufacturer of late-stage clinical biopharmaceutical products created to offer innovative first-in-class drug therapies to treat blinding diseases. The company’s late-stage clinical biopharmaceutical products provide a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork and corneal stroma through an ocular micro injection platform enabling patients suffering from sight threatening diseases such as uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration to avail potentially meaningful treatment benefit.

Acquired by dMed in April 2021.

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. The Company primarily serves emerging and mid-market biopharmaceutical and medical device companies as well as academic medical centers.

Acquired by BioClinica on January 19, 2016.

Developer of an online platform for clinical payments. The company offers a digital payment network that links sponsors to investigators for auditing payment records and compliance.

Code Bio is a preclinical stage company developing novel genetic medicines that leverage the company’s unique, fully synthetic, non-viral delivery platform called 3DNA, which was designed to overcome major barriers currently limiting the nucleic acid field.

Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into one single catheter. By offering embolic protection on the same catheter as a balloon or stent, patients are offered a safer procedure without adding time, complexity, or expense.

Acquired by Veritas Genetics in August 2017.

Provider of genomic and biomedical computing platform intended to empower scientists and clinicians to focus on making breakthrough discoveries and delivering real-world care. The company’s genomic and biomedical computing platform enables patient-level genomic and health data to be securely accessible for drug development and precision medicine, enabling scientists and clinicians to manage, process, analyze and share massive biomedical data sets for everything from genomics to imaging.

IPO in June 2021 (NASDAQ: CVRX).

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. The Barostim neo™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. The Barostim neo can be adjusted to meet each patient’s individual therapy needs.

Developer of a technology designed to extract highly sensitive nucleic acid quantification. The company’s technology uses power of digital PCR in cancer screening and monitoring, point-of-care diagnostics and viral load quantification applications, enabling researchers to get more accurate data, reduce labor cost and make confident decisions.

Provider of a clinical research platform intended to revolutionize the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment and physician participation. The company’s platform breaks down these barriers by providing access to the 97 percent of physicians and patients who do not currently participate in clinical research and by using electronic health records, finds and identifies patients for studies, then provides physicians with the personnel, procedures, technology and infrastructure necessary to conduct the trial in their own clinics, enabling physicians to conduct more efficient and cost-effective trials and gain access to new treatment options, resulting in bringing new therapies to the market faster.

Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

Developer of a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures.

Endogenex is a clinical stage company, that in partnership with Mayo Clinic, was founded to improve outcomes for people living with Type 2 Diabetes. Endogenex’s focus is on the principle that effective treatment for Type 2 Diabetes can extend beyond pharmacologic options and reset the disease process. Through development of the endoscopic ReCET^TM Procedure and the novel application of non-thermal pulsed electric fields, Endogenex is striving to help people with Type 2 Diabetes regain control of their blood glucose levels.

Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply. The company’s biologic and medical device technologies work through pharmaceutical agents that offer enhanced safety and equivalent efficacy for transfusion recipients through the reduction of non-enveloped viruses and elimination of pro-inflammatory factors that can lead to morbidity and mortality, enabling doctors to address the unmet needs in military healthcare involving wound management, tissue repair and hemorrhage control.

IPO in May 2017 (NASDAQ: GTHX).

Developer of novel, small-molecule therapies for the treatment of cancer designed to address significant unmet needs in the treatment of cancer. The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs, a family of proteins that play an important role in the growth and proliferation of cells, enabling the medical industry to treat cancer.

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. The Company’s initial approach applies its Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing its technology through strategic collaborations with pharmaceutical and biotech companies, GeneCentric is defining responder populations based on subtypes throughout the drug development cycle.

GoCheck, a digital health company and creator of GoCheck Kids, serves pediatric teams in their quest to prevent vision impairment, the most prevalent disabling condition among children in the U.S. and many countries. GoCheck Kids is the leading digital vision screening platform for children. 

Gozio promotes loyalty and growth for a health system by creating a system-specific app that enhances the patient experience. From wayfinding to HER integration, Gozio allows health systems to have the flexibility to choose best-of-breed point solutions and integrate them all within the Gozio data hub.

IPO in September 2020 (NASDAQ: GRAY).

Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. The company’s injectable controlled release technologies provide therapeutic levels of sunitinib in preclinical studies reducing the potential frequency of dosing in neovascular age-related macular degeneration (nAMD) from every 4-8 weeks to as few as twice per year, enabling patients to access improved treatment of ocular disease.

Provider of a histotripsy platform designed for the treatment of cancer. The company’s platform uses robotically assisted non-invasive, pulsed sound energy applied from outside the body, which can be used to destroy tissue at the cellular and sub-cellular level, along with an embedded imaging array that provides real-time visual feedback of tissue destruction, to safely, precisely and effectively destroy unwanted tissue throughout the body, reducing patient trauma and healthcare costs.

Huma.ai is a next-generation low code/no code data science solution for the life sciences industry. It has developed a question and answer-based, self-service business intelligence platform that combines the ease of use of Google with the power of business intelligence.

IMMvention is developing novel, first-in-class therapies for treating hemolytic anemias.

Acquired by Aledade in January 2022.

Tech-enabled service offering for advanced care planning, driving palliative care utilization, a reduction in end-of-life medical costs and an improvement in quality of life. Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. End-of-life care is a massive cost driver is US health system; the company is selling to managed care organizations, insurance providers, and ACOs.

iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations.

MediKidz, Inc, DBA Jumo Health

Founded by pediatricians, developing medical content in an educational format embraced by children. Selling disease-focused books, videos and other content to marketing departments of pharma companies, hospitals, and consumers.

IPO in August 2020 (NASDAQ: KYMR).

Kymera is developing a heterobifunctional small molecule drug platform to target previously undruggable proteins for degradation. Using a new therapeutic modality, Kymera’s therapeutics redirect the ubiquitin proteosome system for targeted protein degradation.

Acquired by Bial in October 2020.

Developer of innovative neurodegeneration small-molecules intended to establish a unique and effective platform for novel drug discovery. The company’s innovative neurodegeneration small-molecules leverages the clinically validated link between lysosome-based genetic disorders and neurodegenerative diseases, enabling health institutions to avail provision of new treatment options for patients with severe neurological diseases.

Acquired by MextGen Healthcare in December 2019.

Provider of patient experience platform designed to facilitate the relationship between physicians and patients. The company’s patient experience platform focuses on the optimal patient experience for paying a bill, requesting a prescription renewal, or asking a question thereby enabling healthcare facilities to operate more efficiently and effectively.

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages. 

Developing first-in-class approach to activate myeloid cells to kill cancer. 

HcT2 Co. DBA Nurse Grid

Acquired by HealthStream in March 2020.

Developer of staffing, communication and schedule management tools designed to modernize staffing processes for healthcare facilities. The company’s simplified schedule management tools help healthcare departments to manage schedules, fill open shifts, increase staff satisfaction, and boost retention enabling healthcare facilities to uniquely engage and connect with nurses to make their lives easier, to drive a broad set of efficiencies, and for health system customers to improve employee retention and job satisfaction.

Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders. The company’s platform combines natural compounds with various pharmaceutical agents, enabling healthcare professionals to use natural compounds to create synergy with known pharmaceuticals to prevent and treat chronic diseases resulting from over-nutrition and aging.

Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion with a novel mechanism in the context of several retinal diseases including glaucoma, non-proliferative diabetic retinopathy, and intermediate age-related macular degeneration.  The company was founded by OrbiMed Advisors and is supported by a syndicate of investors including Camden Partners, Lilly Asia Ventures, and Wu Capital.

IPO in October, 2018 (NASDAQ:PHAS).

PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) was founded to commercialize applications of elastin-like polypeptides (ELPs), whose properties give them utility in a variety of applications in human medicine, including production, purification, and delivery of protein and peptide therapeutics. The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. The company’s technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases.

Developer of a molecular diagnostics technology designed to dramatically reduce time to results in microbiology. The company’s Field Activated Sample Treatment (FAST) technology uses a novel electrical lysing and sample treatment technique that enables the rapid detection of infectious agents in a direct blood sample, enabling clinicians to detect and identify micro-organisms in infected whole blood samples without the need for culturing or time consuming sample processing.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

Acquired by NASDAQ: ALKS in Nov 2019

Rodin is developing a differentiated approach to Alzheimer’s through targeted epigenetic regulation of synaptic function and health by HDAC complex modulation. Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. The company’s epigenetic drugs are harnessing the power of epigenetic regulation of neuronal function by HDAC complex modulation, enabling patients to restore synaptic function, health and survival in degenerative brain diseases.

Across the United States, fast-growing populations increasingly require access to critical healthcare services like dialysis infusions, oncology visits, methadone treatments, or day-to-day wellness visits. Simultaneously, the industry is shifting from fee-for-service reimbursement to value-based care.

SafeRide Health, founded in 2016, keenly understands and operates at the center of these trends. SafeRide’s mission is to reconnect the nation’s poor and sick to care while eliminating barriers plaguing the medical transportation industry today.

SafeRide Health empowers health plans to manage their members with more intelligence and control. SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency. SafeRide then tailors managed services to each health plan’s unique needs and goals. We are thrilled to partner with the nation’s leading healthcare providers who entrust SafeRide Health with increasing patient access to care.

Seaport Diagnostics’s mission is to help lead the way in changing the diagnostic testing landscape by increasing its accessibility. On the foundation of automation, software, and logistics technologies utilized in our CLIA-certified laboratories, we have been able to seamlessly embark on our next phase as a company into the clinical diagnostics field. We now offer COVID-19 testing, respiratory pathogen testing, molecular UTI testing, and HbA1c testing in addition to our consumer genetic testing and personalized vitamins.

IPO in October 2020 (NASDAQ: STTK).

Shattuck Labs is a clinical-stage biotechnology company pioneering the development of a novel class of bi-functional fusion proteins for the treatment of cancer and autoimmune disease. Shattuck’s Agonist Redirected Checkpoint (ARC) technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.

Acquired by Teleflex in September 2022.

Standard Bariatrics is developing a clamp and stapler to standardize sleeve gastrectomy procedures, the most widely performed weight loss procedure today. The company’s surgical tools are FDA Cleared and are used in conjunction with current general use endoscopic staplers that have 6cm reloadable cartridges, which also reduces the number of cartridges used in a sleeve on average from 6 cartridges to 4 cartridges, enabling surgeons to reduce costs, standardize their approach and create great sleeve anatomy every time.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

Synaptrix, a spin-out medical device company, is focused on developing and commercializing drug-free, long-lasting solutions for post-operative pain management. Our proprietary NOVABLOC™ system is a procedure-based solution that delivers a novel type of electrical stimulation to selectively blocks pain signal transmission. Through human feasibility studies we have demonstrated 20+ days of pain relief with a single treatment, while sparing motor function, touch and proprioception. Synaptrix aims to receive FDA clearance in 2026 and begin commercialization of the NOVABLOC™ system.

Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases. We are leveraging our proprietary in silico platform BEYOND to generate novel therapeutics to hit previously undruggable targets while bringing the paradigm of durable response into early drug design through our unique ability to predict and overcome drug resistance.

Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering. The company’s therapeutic application is developed using a regenerative approach based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1) to treat endothelial cell mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases.

Tune Therapeutics is a cutting-edge biotechnology company founded by world-class leaders in epigenome editing. Tune strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases. Join a highly skilled and dynamic team with expertise that spans basic discovery all the way to clinical implementation. We are passionate about the technology and its potential to help patients in need. 

Veralox is developing first-in-class therapeutics targeting 12-lipoxygenase (12-LOX), initially for the treatment of heparin-induced thrombocytopenia and thrombosis (HITT). The company’s lead drug has potential to be a game-changer in the treatment of HITT based on predicted clinical outcomes (efficacy, safety, and healthcare economics).

Acquired by NovaQuest Capital Management in January 2018.

Developer of therapies based on metalloenzyme chemistry and biology platform. The company focuses on the discovery, development, and commercialization of novel therapeutic agents that target metalloenzymes or interfere with the cell’s ability to effectively utilize critical metal ions including zinc and iron for invasive and hospital-based fungal infections, cancer, cardiovascular and orphan diseases, enabling the patients and clinicians to provide greater selectivity and safety as well as improved potency compared to currently available therapeutics.

IPO in January 2022 (NASDAQ: VIGL).

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

Developer of health engagement platform intended to connect families to health resources on the smartphone. The company’s platform includes mobile maternity program that uses self-reported data to identify high-risk pregnancies and drive interventions by delivering customized tools and content, enabling users to promote healthy pregnancies, track family health and support the growth of each family member based on their individual health needs over time.

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.

IPO in March 2022 (NASDAQ: ANTX)

AN2 Therapeutics (“AN2”) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives.

AN2 is a mission-driven company. We have a passion for improving global public health and a vision to accelerate development of novel medicines to treat serious infectious diseases and save lives worldwide.

Acquired by PerkinElmer (NYS: PKI) in March 2011.

Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. The company offers Ensemble for Life Science, an on-demand software platform, that blends social networking, collaboration, and refined scientific data mining to assist internal and external research communication and management. It provides Ensemble Electronic Lab Notebook that allows users to capture experimental data, results, and decision support needs for their organization medicinal chemistry, biologists, and bio-analytical departments; and Ensemble Toolkits, enabling users to integrate components utilized inside platform technology into their application or environment.

AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart. The system is being developed to simplify and improve management of patients requiring temporary pacing as well as those with a need for permanent pacing. Initial clinical feasibility has been demonstrated and the company is now well-positioned to develop the technology through pivotal studies and regulatory approval.

Atsena Therapeutics is a clinical-stage, ophthalmology-focused gene therapy company based on research from Dr. Shannon Boye’s lab at the University of Florida. 

Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs. It focuses on commercializing neuromodulation technology platforms designed to treat patients suffering from chronic diseases.

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University.

The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.

BEKHealth accelerates clinical research by providing EMR data processing, feasibility and site selection, precision patient matching and care coordination. Their clinical research software accelerates timelines by automating multiple high impact processes.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

Click the logo for information on Boomerang’s clinical trial

Boomerang Medical is developing a technology to advance the treatment of autoimmune diseases by using electrical nerve stimulation to manage inflammation and immune response.

Boston Immune Technologies and Therapeutics (BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases.

Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

IPO in June, 2016 (NASDAQ:CLSD).

Manufacturer of late-stage clinical biopharmaceutical products created to offer innovative first-in-class drug therapies to treat blinding diseases. The company’s late-stage clinical biopharmaceutical products provide a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork and corneal stroma through an ocular micro injection platform enabling patients suffering from sight threatening diseases such as uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration to avail potentially meaningful treatment benefit.

Acquired by dMed in April 2021.

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. The Company primarily serves emerging and mid-market biopharmaceutical and medical device companies as well as academic medical centers.

Acquired by BioClinica on January 19, 2016.

Developer of an online platform for clinical payments. The company offers a digital payment network that links sponsors to investigators for auditing payment records and compliance.

Code Bio is a preclinical stage company developing novel genetic medicines that leverage the company’s unique, fully synthetic, non-viral delivery platform called 3DNA, which was designed to overcome major barriers currently limiting the nucleic acid field.

Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into one single catheter. By offering embolic protection on the same catheter as a balloon or stent, patients are offered a safer procedure without adding time, complexity, or expense.

Acquired by Veritas Genetics in August 2017.

Provider of genomic and biomedical computing platform intended to empower scientists and clinicians to focus on making breakthrough discoveries and delivering real-world care. The company’s genomic and biomedical computing platform enables patient-level genomic and health data to be securely accessible for drug development and precision medicine, enabling scientists and clinicians to manage, process, analyze and share massive biomedical data sets for everything from genomics to imaging.

IPO in June 2021 (NASDAQ: CVRX).

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. The Barostim neo™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. The Barostim neo can be adjusted to meet each patient’s individual therapy needs.

Developer of a technology designed to extract highly sensitive nucleic acid quantification. The company’s technology uses power of digital PCR in cancer screening and monitoring, point-of-care diagnostics and viral load quantification applications, enabling researchers to get more accurate data, reduce labor cost and make confident decisions.

Provider of a clinical research platform intended to revolutionize the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment and physician participation. The company’s platform breaks down these barriers by providing access to the 97 percent of physicians and patients who do not currently participate in clinical research and by using electronic health records, finds and identifies patients for studies, then provides physicians with the personnel, procedures, technology and infrastructure necessary to conduct the trial in their own clinics, enabling physicians to conduct more efficient and cost-effective trials and gain access to new treatment options, resulting in bringing new therapies to the market faster.

Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

Developer of a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures.

Endogenex is a clinical stage company, that in partnership with Mayo Clinic, was founded to improve outcomes for people living with Type 2 Diabetes. Endogenex’s focus is on the principle that effective treatment for Type 2 Diabetes can extend beyond pharmacologic options and reset the disease process. Through development of the endoscopic ReCET^TM Procedure and the novel application of non-thermal pulsed electric fields, Endogenex is striving to help people with Type 2 Diabetes regain control of their blood glucose levels.

Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply. The company’s biologic and medical device technologies work through pharmaceutical agents that offer enhanced safety and equivalent efficacy for transfusion recipients through the reduction of non-enveloped viruses and elimination of pro-inflammatory factors that can lead to morbidity and mortality, enabling doctors to address the unmet needs in military healthcare involving wound management, tissue repair and hemorrhage control.

IPO in May 2017 (NASDAQ: GTHX).

Developer of novel, small-molecule therapies for the treatment of cancer designed to address significant unmet needs in the treatment of cancer. The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs, a family of proteins that play an important role in the growth and proliferation of cells, enabling the medical industry to treat cancer.

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. The Company’s initial approach applies its Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing its technology through strategic collaborations with pharmaceutical and biotech companies, GeneCentric is defining responder populations based on subtypes throughout the drug development cycle.

GoCheck, a digital health company and creator of GoCheck Kids, serves pediatric teams in their quest to prevent vision impairment, the most prevalent disabling condition among children in the U.S. and many countries. GoCheck Kids is the leading digital vision screening platform for children. 

Gozio promotes loyalty and growth for a health system by creating a system-specific app that enhances the patient experience. From wayfinding to HER integration, Gozio allows health systems to have the flexibility to choose best-of-breed point solutions and integrate them all within the Gozio data hub.

IPO in September 2020 (NASDAQ: GRAY).

Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. The company’s injectable controlled release technologies provide therapeutic levels of sunitinib in preclinical studies reducing the potential frequency of dosing in neovascular age-related macular degeneration (nAMD) from every 4-8 weeks to as few as twice per year, enabling patients to access improved treatment of ocular disease.

Provider of a histotripsy platform designed for the treatment of cancer. The company’s platform uses robotically assisted non-invasive, pulsed sound energy applied from outside the body, which can be used to destroy tissue at the cellular and sub-cellular level, along with an embedded imaging array that provides real-time visual feedback of tissue destruction, to safely, precisely and effectively destroy unwanted tissue throughout the body, reducing patient trauma and healthcare costs.

Huma.ai is a next-generation low code/no code data science solution for the life sciences industry. It has developed a question and answer-based, self-service business intelligence platform that combines the ease of use of Google with the power of business intelligence.

IMMvention is developing novel, first-in-class therapies for treating hemolytic anemias.

Acquired by Aledade in January 2022.

Tech-enabled service offering for advanced care planning, driving palliative care utilization, a reduction in end-of-life medical costs and an improvement in quality of life. Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. End-of-life care is a massive cost driver is US health system; the company is selling to managed care organizations, insurance providers, and ACOs.

iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations.

MediKidz, Inc, DBA Jumo Health

Founded by pediatricians, developing medical content in an educational format embraced by children. Selling disease-focused books, videos and other content to marketing departments of pharma companies, hospitals, and consumers.

IPO in August 2020 (NASDAQ: KYMR).

Kymera is developing a heterobifunctional small molecule drug platform to target previously undruggable proteins for degradation. Using a new therapeutic modality, Kymera’s therapeutics redirect the ubiquitin proteosome system for targeted protein degradation.

Acquired by Bial in October 2020.

Developer of innovative neurodegeneration small-molecules intended to establish a unique and effective platform for novel drug discovery. The company’s innovative neurodegeneration small-molecules leverages the clinically validated link between lysosome-based genetic disorders and neurodegenerative diseases, enabling health institutions to avail provision of new treatment options for patients with severe neurological diseases.

Acquired by MextGen Healthcare in December 2019.

Provider of patient experience platform designed to facilitate the relationship between physicians and patients. The company’s patient experience platform focuses on the optimal patient experience for paying a bill, requesting a prescription renewal, or asking a question thereby enabling healthcare facilities to operate more efficiently and effectively.

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages. 

Developing first-in-class approach to activate myeloid cells to kill cancer. 

HcT2 Co. DBA Nurse Grid

Acquired by HealthStream in March 2020.

Developer of staffing, communication and schedule management tools designed to modernize staffing processes for healthcare facilities. The company’s simplified schedule management tools help healthcare departments to manage schedules, fill open shifts, increase staff satisfaction, and boost retention enabling healthcare facilities to uniquely engage and connect with nurses to make their lives easier, to drive a broad set of efficiencies, and for health system customers to improve employee retention and job satisfaction.

Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders. The company’s platform combines natural compounds with various pharmaceutical agents, enabling healthcare professionals to use natural compounds to create synergy with known pharmaceuticals to prevent and treat chronic diseases resulting from over-nutrition and aging.

Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion with a novel mechanism in the context of several retinal diseases including glaucoma, non-proliferative diabetic retinopathy, and intermediate age-related macular degeneration.  The company was founded by OrbiMed Advisors and is supported by a syndicate of investors including Camden Partners, Lilly Asia Ventures, and Wu Capital.

IPO in October, 2018 (NASDAQ:PHAS).

PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) was founded to commercialize applications of elastin-like polypeptides (ELPs), whose properties give them utility in a variety of applications in human medicine, including production, purification, and delivery of protein and peptide therapeutics. The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. The company’s technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases.

Developer of a molecular diagnostics technology designed to dramatically reduce time to results in microbiology. The company’s Field Activated Sample Treatment (FAST) technology uses a novel electrical lysing and sample treatment technique that enables the rapid detection of infectious agents in a direct blood sample, enabling clinicians to detect and identify micro-organisms in infected whole blood samples without the need for culturing or time consuming sample processing.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

Acquired by NASDAQ: ALKS in Nov 2019

Rodin is developing a differentiated approach to Alzheimer’s through targeted epigenetic regulation of synaptic function and health by HDAC complex modulation. Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. The company’s epigenetic drugs are harnessing the power of epigenetic regulation of neuronal function by HDAC complex modulation, enabling patients to restore synaptic function, health and survival in degenerative brain diseases.

Across the United States, fast-growing populations increasingly require access to critical healthcare services like dialysis infusions, oncology visits, methadone treatments, or day-to-day wellness visits. Simultaneously, the industry is shifting from fee-for-service reimbursement to value-based care.

SafeRide Health, founded in 2016, keenly understands and operates at the center of these trends. SafeRide’s mission is to reconnect the nation’s poor and sick to care while eliminating barriers plaguing the medical transportation industry today.

SafeRide Health empowers health plans to manage their members with more intelligence and control. SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency. SafeRide then tailors managed services to each health plan’s unique needs and goals. We are thrilled to partner with the nation’s leading healthcare providers who entrust SafeRide Health with increasing patient access to care.

Seaport Diagnostics’s mission is to help lead the way in changing the diagnostic testing landscape by increasing its accessibility. On the foundation of automation, software, and logistics technologies utilized in our CLIA-certified laboratories, we have been able to seamlessly embark on our next phase as a company into the clinical diagnostics field. We now offer COVID-19 testing, respiratory pathogen testing, molecular UTI testing, and HbA1c testing in addition to our consumer genetic testing and personalized vitamins.

IPO in October 2020 (NASDAQ: STTK).

Shattuck Labs is a clinical-stage biotechnology company pioneering the development of a novel class of bi-functional fusion proteins for the treatment of cancer and autoimmune disease. Shattuck’s Agonist Redirected Checkpoint (ARC) technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.

Acquired by Teleflex in September 2022.

Standard Bariatrics is developing a clamp and stapler to standardize sleeve gastrectomy procedures, the most widely performed weight loss procedure today. The company’s surgical tools are FDA Cleared and are used in conjunction with current general use endoscopic staplers that have 6cm reloadable cartridges, which also reduces the number of cartridges used in a sleeve on average from 6 cartridges to 4 cartridges, enabling surgeons to reduce costs, standardize their approach and create great sleeve anatomy every time.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

Synaptrix, a spin-out medical device company, is focused on developing and commercializing drug-free, long-lasting solutions for post-operative pain management. Our proprietary NOVABLOC™ system is a procedure-based solution that delivers a novel type of electrical stimulation to selectively blocks pain signal transmission. Through human feasibility studies we have demonstrated 20+ days of pain relief with a single treatment, while sparing motor function, touch and proprioception. Synaptrix aims to receive FDA clearance in 2026 and begin commercialization of the NOVABLOC™ system.

Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases. We are leveraging our proprietary in silico platform BEYOND to generate novel therapeutics to hit previously undruggable targets while bringing the paradigm of durable response into early drug design through our unique ability to predict and overcome drug resistance.

Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering. The company’s therapeutic application is developed using a regenerative approach based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1) to treat endothelial cell mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases.

Tune Therapeutics is a cutting-edge biotechnology company founded by world-class leaders in epigenome editing. Tune strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases. Join a highly skilled and dynamic team with expertise that spans basic discovery all the way to clinical implementation. We are passionate about the technology and its potential to help patients in need. 

Veralox is developing first-in-class therapeutics targeting 12-lipoxygenase (12-LOX), initially for the treatment of heparin-induced thrombocytopenia and thrombosis (HITT). The company’s lead drug has potential to be a game-changer in the treatment of HITT based on predicted clinical outcomes (efficacy, safety, and healthcare economics).

Acquired by NovaQuest Capital Management in January 2018.

Developer of therapies based on metalloenzyme chemistry and biology platform. The company focuses on the discovery, development, and commercialization of novel therapeutic agents that target metalloenzymes or interfere with the cell’s ability to effectively utilize critical metal ions including zinc and iron for invasive and hospital-based fungal infections, cancer, cardiovascular and orphan diseases, enabling the patients and clinicians to provide greater selectivity and safety as well as improved potency compared to currently available therapeutics.

IPO in January 2022 (NASDAQ: VIGL).

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

Developer of health engagement platform intended to connect families to health resources on the smartphone. The company’s platform includes mobile maternity program that uses self-reported data to identify high-risk pregnancies and drive interventions by delivering customized tools and content, enabling users to promote healthy pregnancies, track family health and support the growth of each family member based on their individual health needs over time.

Configo Health is a healthcare benchmarking and analytics company, focused exclusively on pediatrics, that helps children’s hospitals and their teams make better decisions through the use of timely, trusted and actionable insights.

GoCheck, a digital health company and creator of GoCheck Kids, serves pediatric teams in their quest to prevent vision impairment, the most prevalent disabling condition among children in the U.S. and many countries. GoCheck Kids is the leading digital vision screening platform for children. 

Founded in 2009 in Asheville, NC, ilumivu began with a software platform, mEMA, supporting intervention-based healthcare research conducted at university hospitals and healthcare research organizations worldwide. In October 2021, ilumivu merged with Cardiogram, a leading heart health app with a large user base and backed by clinically-validated AI/ML models.

Rx Redefined is a platform that allows physicians to directly manage the distribution of medical supplies to their patients, positively impacting the quality of care, improving access to care and reducing costs.

Configo Health is a healthcare benchmarking and analytics company, focused exclusively on pediatrics, that helps children’s hospitals and their teams make better decisions through the use of timely, trusted and actionable insights.

GoCheck, a digital health company and creator of GoCheck Kids, serves pediatric teams in their quest to prevent vision impairment, the most prevalent disabling condition among children in the U.S. and many countries. GoCheck Kids is the leading digital vision screening platform for children. 

Founded in 2009 in Asheville, NC, ilumivu began with a software platform, mEMA, supporting intervention-based healthcare research conducted at university hospitals and healthcare research organizations worldwide. In October 2021, ilumivu merged with Cardiogram, a leading heart health app with a large user base and backed by clinically-validated AI/ML models.

Rx Redefined is a platform that allows physicians to directly manage the distribution of medical supplies to their patients, positively impacting the quality of care, improving access to care and reducing costs.

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Developer of a local anesthetic delivery system intended to enhance a patient’s visit by reducing pain and shortening procedure time. The company’s system reduces the burning sensation a patient feels when they receive an injection, offers smooth, streamlined workflow, saves significant time and improves the entire dental experience for patients, enabling dentists to increase their efficiency, predictability and profitability.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

Boragen is a small molecule development company located in Durham, NC focused on leveraging the unique chemical properties of Boron chemistry, both in crop protection and animal health. The chemistry platform developed by Boragen focuses on reducing pesticide use through innovative, synergistic combinations.

Camras Vision is currently developing a glaucoma therapy that is intended to not only circumvent the complications present with glaucoma surgery, but also to provide ophthalmologists with the first tool that can stop the progression of glaucoma. The key innovation of the Camras Shunt is that it drains aqueous humor externally, thereby avoiding the complications and failure due to scarring within the drainage site that is associated with all other incisional/shunt surgeries.

Pack and Purchase, Inc. DBA Canopy

Canopy is disrupting a large, fragmented, and stagnant market, creating a modernized home lawn care experience for customers. Two-fold growth opportunity through organic and word of mouth and also growth plan to quickly capture market share in cities across the Southeast and out to the rest of the U.S. Efficient systems and operations platform and partnership with Lowe’s creates a scalable business that can rapidly expand sticky customer base, with over 50% over current customers buying into full service modules.

Manufacturer and seller of an antiperspirant hand and foot lotion created to stop sweat in one’s hands and feet. The company’s lotion is a non-greasy, no-residue and no-irritation product containing natural eucalyptus oil to give a smooth feel, enabling customers to get rid of the problem of sweaty hands and feet in a safe, effective and easy way.

Emergo Therapeutics is reformulating existing drugs for the treatment of symptoms caused by inflammatory response in influenza like illnesses. They are focused on developing drugs to modulate inflammatory cytokines and improve immune system response in infectious disease indications as an adjunct treatment to existing antiviral medications.

FilterEasy provides scheduled shipments of airfilters directly to your home. Many american’s don’t have a service to change their filters. As a result, their filters go unchanged for months and even years. The complications of not changing your homes airfilter range from efficiency of heating and cooling your home, to potenital air quality risks. FilterEasy is out of Raleigh, NC and has found a way to get more people to change their airfilters and at an affordable rate.

Developer of a predictive analytics and machine learning platform designed to help real estate professionals to generate sales leads. The company’s predictive analytics and machine learning platform combines people and data science to get transactions from the relationships by analyzing an agent’s network, contact list, database, and the social connections that identifies the people most likely to sell in the next six to twelve months, enabling real estate business in identifying their potential customers.

Producer of meat sybstitute food products. The company specializes in producing and selling vegetable-based meat substitute products that can be breaded, baked, stir-fried, fried, grilled, sautéed, or microwaved.

Developer of medical devices designed to offer vascular access for hemodialysis. The company’s devices modify existing synthetic vascular grafts for hemodialysis access, prevent needle cannulation injuries and facilitate graft access safety, enabling physicians to reduce the potential for adverse events and device failures associated with repeated vascular access.

Operator of a community marketplace for businesses to locate, discover and rent specialized equipment. The company operates an online equipment rental marketplace where businesses can locate and rent the equipment they need from a global network of suppliers.

Mati Energy is a Durham, NC-based LLC that provides a healthy energy drink for consumers that want a healthier and more effective alternative to traditional caffeinated/energy drinks such as coffee, Red Bull or Monster. Mati is brewed from the second most caffeinated plant in the world behind coffee, Guayusa, which is incredibly rich in antioxidants, potassium, magnesium, amino acids, and theobromine. The duration of the heightened intensity is longer than coffee or the more well-known energy drinks.

Provider of naturally effective insect repellents intended to change category norms by turning repellents into a lifestyle brand. The company’s products are innovative, effective, non-toxic, healthy and beautifully balanced, enabling users to repel insects without unhealthy side effects. ***pitchbook

Acquired by Target RWE in December 2020.

NoviSci is a healthcare IT and services company with the mission of facilitating learning from real-world data (RWD) and real-world evidence (RWE). The company was founded based on the research of Drs. Alan Brookhart and Steve Cole, renowned professors/experts in causal inference and epidemiology from The University of North Carolina at Chapel Hill.

Developer of a healthcare management software designed to help hospital pharmacy team improve medication shortage. The company’s software facilitates users to easily visualize, optimize and customize their rapidly expanding portfolio of pharmacy automation systems regardless of vendor, enabling healthcare professionals to manage the workflow and data challenges of ongoing medication shortages.

Developer of personalized therapies designed to revolutionize the next generation precision poly therapy dosing and delivery. The company’s personalized therapies are fast, safe, accurate and efficient with enhanced CGMP compliance, enabling physicians to treat their patients in an enhanced way.

PRSONAS has focused their initial product efforts on holographic displays for use in the office environment (as virtual receptionists), for product display and demonstration in trade show applications (virtual product specialist), and for concierge services.

Developer of an AI platform intended to provide the accuracy and security features necessary for enterprise applications. The company’s platform uses a virtual assistant, enabling clients to increase customer engagement, employee productivity and ecosystem collaboration.

Additive Device, Inc. dba Restor3d

Restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants.

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

Developer of online decision tools designed to simplify later-life decision making for the aging and their caregivers. The company’s online tools platform helps older adults and their families make informed long-term care decisions around issues like driving, home safety and dementia, enabling families to improve health and wellness outcomes to lower costs for all stakeholders in the continuum of care.

Developer of LiDAR and 3D sensor technologies designed for autonomous vehicles and industrial automation. The company’s system captures the entire frame at once-just like a camera, enabling users to get a modular, scalable and reliable Flash LiDAR that delivers high-performance, long-range 3D sensing.

Developer of sports officiating marketplace designed to modernize and standardize refereeing management and payment for leagues. The company’s marketplace offers easy access, better alignment and transparency between officials and games by posting games online via its application, enabling qualified officials to select, work, provide feedback and receive automatic digital payment.

Skyline Vet Pharma is a veterinary pharmaceutical company that uses new delivery technologies to reformulate drugs with established animal health markets. Their innovation comes from the methods of drug delivery in animals as opposed to drug discovery.

Born & raised in North Carolina’s Research Triangle Park, Spiffy has always had an affinity for technology. The Spiffy app allows customers to conveniently schedule, track and pay for high-quality car washing services at the time and location of their choosing. No longer do consumers have to deal with inconvenient, inconsistent and frustrating visits to fixed car wash locations. With Spiffy, customers can do more than just wash their car with their phone – Spiffy turns any parking space into a car wash.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

Developer of biodegradable foams and powders designed to remove salt and minerals from industrial and naturally occurring brines. The company’s biodegradable foams and powders binds with dissolved salts, minerals and other materials, helping it to get removed from waste water, enabling governments and industries recycle water in an eco-friendly and cost effective manner.

Owner and operator of a technology company intended to use humanity’s science and technology to solve climate problems. The company’s climate risk analytics software quantifies financial impact of climate on investment portfolios using machine learning, big climate, socioeconomic data and available physical or economic science, enabling business leaders to measure, monitor and manage their climate risks and opportunities.

Developer of a Saas-based cybersecurity software intended to manage security compliance. The company’s software permits building a compliant against insider threat program, track training, manage reporting requirements and prepare for inspections, enabling security managers at federal contractors to stay compliant with NISPOM regulations.

Owner and operator of a sensor development and data management company intended to provide report on vehicular tire tread-wear in real time. The company’s sensors are wireless utilizes sensor technology using carbon nano-tubes and can signal to replace tires or report information about uneven and often dangerous tire wear conditions, enabling users to maintain and keep a track of wear and tear of their automobile tires.

Agtech Accelerator – Vindara, Inc.

Addressing the strategic ATA technology scouting pillar “Novel Farming Systems”, Vindara seeks to address the breeding and biotechnology gap in the vertical farming market. Combining IP enabled genetics into commercialized form factors leverages ATA’s expertise in plant science while capturing the largest value within the food supply chain.

Operator of a health supplements company intended to offer natural supplements for various diseases. The company’s supplements are made from all natural ingredients such as lutein, melatonin, bacopa, allicin, vitex and garlic and it also provides health information to users, enabling individuals to intake organic supplements and recover diseases.

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016.

Developer of a local anesthetic delivery system intended to enhance a patient’s visit by reducing pain and shortening procedure time. The company’s system reduces the burning sensation a patient feels when they receive an injection, offers smooth, streamlined workflow, saves significant time and improves the entire dental experience for patients, enabling dentists to increase their efficiency, predictability and profitability.

Acquired by Press Ganey Associates in January 2018.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform to improve quality metrics and drive additional revenue for providers. The Company’s platform enables real-time patient-generated data for administrators to act upon in order to improve their operations as well as patient satisfaction and retention.

Boragen is a small molecule development company located in Durham, NC focused on leveraging the unique chemical properties of Boron chemistry, both in crop protection and animal health. The chemistry platform developed by Boragen focuses on reducing pesticide use through innovative, synergistic combinations.

Camras Vision is currently developing a glaucoma therapy that is intended to not only circumvent the complications present with glaucoma surgery, but also to provide ophthalmologists with the first tool that can stop the progression of glaucoma. The key innovation of the Camras Shunt is that it drains aqueous humor externally, thereby avoiding the complications and failure due to scarring within the drainage site that is associated with all other incisional/shunt surgeries.

Pack and Purchase, Inc. DBA Canopy

Canopy is disrupting a large, fragmented, and stagnant market, creating a modernized home lawn care experience for customers. Two-fold growth opportunity through organic and word of mouth and also growth plan to quickly capture market share in cities across the Southeast and out to the rest of the U.S. Efficient systems and operations platform and partnership with Lowe’s creates a scalable business that can rapidly expand sticky customer base, with over 50% over current customers buying into full service modules.

Manufacturer and seller of an antiperspirant hand and foot lotion created to stop sweat in one’s hands and feet. The company’s lotion is a non-greasy, no-residue and no-irritation product containing natural eucalyptus oil to give a smooth feel, enabling customers to get rid of the problem of sweaty hands and feet in a safe, effective and easy way.

Emergo Therapeutics is reformulating existing drugs for the treatment of symptoms caused by inflammatory response in influenza like illnesses. They are focused on developing drugs to modulate inflammatory cytokines and improve immune system response in infectious disease indications as an adjunct treatment to existing antiviral medications.

FilterEasy provides scheduled shipments of airfilters directly to your home. Many american’s don’t have a service to change their filters. As a result, their filters go unchanged for months and even years. The complications of not changing your homes airfilter range from efficiency of heating and cooling your home, to potenital air quality risks. FilterEasy is out of Raleigh, NC and has found a way to get more people to change their airfilters and at an affordable rate.

Developer of a predictive analytics and machine learning platform designed to help real estate professionals to generate sales leads. The company’s predictive analytics and machine learning platform combines people and data science to get transactions from the relationships by analyzing an agent’s network, contact list, database, and the social connections that identifies the people most likely to sell in the next six to twelve months, enabling real estate business in identifying their potential customers.

Producer of meat sybstitute food products. The company specializes in producing and selling vegetable-based meat substitute products that can be breaded, baked, stir-fried, fried, grilled, sautéed, or microwaved.

Developer of medical devices designed to offer vascular access for hemodialysis. The company’s devices modify existing synthetic vascular grafts for hemodialysis access, prevent needle cannulation injuries and facilitate graft access safety, enabling physicians to reduce the potential for adverse events and device failures associated with repeated vascular access.

Operator of a community marketplace for businesses to locate, discover and rent specialized equipment. The company operates an online equipment rental marketplace where businesses can locate and rent the equipment they need from a global network of suppliers.

Mati Energy is a Durham, NC-based LLC that provides a healthy energy drink for consumers that want a healthier and more effective alternative to traditional caffeinated/energy drinks such as coffee, Red Bull or Monster. Mati is brewed from the second most caffeinated plant in the world behind coffee, Guayusa, which is incredibly rich in antioxidants, potassium, magnesium, amino acids, and theobromine. The duration of the heightened intensity is longer than coffee or the more well-known energy drinks.

Provider of naturally effective insect repellents intended to change category norms by turning repellents into a lifestyle brand. The company’s products are innovative, effective, non-toxic, healthy and beautifully balanced, enabling users to repel insects without unhealthy side effects. ***pitchbook

Acquired by Target RWE in December 2020.

NoviSci is a healthcare IT and services company with the mission of facilitating learning from real-world data (RWD) and real-world evidence (RWE). The company was founded based on the research of Drs. Alan Brookhart and Steve Cole, renowned professors/experts in causal inference and epidemiology from The University of North Carolina at Chapel Hill.

Developer of a healthcare management software designed to help hospital pharmacy team improve medication shortage. The company’s software facilitates users to easily visualize, optimize and customize their rapidly expanding portfolio of pharmacy automation systems regardless of vendor, enabling healthcare professionals to manage the workflow and data challenges of ongoing medication shortages.

Developer of personalized therapies designed to revolutionize the next generation precision poly therapy dosing and delivery. The company’s personalized therapies are fast, safe, accurate and efficient with enhanced CGMP compliance, enabling physicians to treat their patients in an enhanced way.

PRSONAS has focused their initial product efforts on holographic displays for use in the office environment (as virtual receptionists), for product display and demonstration in trade show applications (virtual product specialist), and for concierge services.

Developer of an AI platform intended to provide the accuracy and security features necessary for enterprise applications. The company’s platform uses a virtual assistant, enabling clients to increase customer engagement, employee productivity and ecosystem collaboration.

Additive Device, Inc. dba Restor3d

Restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants.

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure. By using three-dimensional RNA structure, the platform enables targeting of thousands of previously undruggable RNAs, expanding the druggable genome by 60-fold. Structures acquired from this platform will be used to develop small molecules that bind functional and therapeutically relevant regions of RNA.

Developer of online decision tools designed to simplify later-life decision making for the aging and their caregivers. The company’s online tools platform helps older adults and their families make informed long-term care decisions around issues like driving, home safety and dementia, enabling families to improve health and wellness outcomes to lower costs for all stakeholders in the continuum of care.

Developer of LiDAR and 3D sensor technologies designed for autonomous vehicles and industrial automation. The company’s system captures the entire frame at once-just like a camera, enabling users to get a modular, scalable and reliable Flash LiDAR that delivers high-performance, long-range 3D sensing.

Developer of sports officiating marketplace designed to modernize and standardize refereeing management and payment for leagues. The company’s marketplace offers easy access, better alignment and transparency between officials and games by posting games online via its application, enabling qualified officials to select, work, provide feedback and receive automatic digital payment.

Skyline Vet Pharma is a veterinary pharmaceutical company that uses new delivery technologies to reformulate drugs with established animal health markets. Their innovation comes from the methods of drug delivery in animals as opposed to drug discovery.

Born & raised in North Carolina’s Research Triangle Park, Spiffy has always had an affinity for technology. The Spiffy app allows customers to conveniently schedule, track and pay for high-quality car washing services at the time and location of their choosing. No longer do consumers have to deal with inconvenient, inconsistent and frustrating visits to fixed car wash locations. With Spiffy, customers can do more than just wash their car with their phone – Spiffy turns any parking space into a car wash.

StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies

Developer of biodegradable foams and powders designed to remove salt and minerals from industrial and naturally occurring brines. The company’s biodegradable foams and powders binds with dissolved salts, minerals and other materials, helping it to get removed from waste water, enabling governments and industries recycle water in an eco-friendly and cost effective manner.

Owner and operator of a technology company intended to use humanity’s science and technology to solve climate problems. The company’s climate risk analytics software quantifies financial impact of climate on investment portfolios using machine learning, big climate, socioeconomic data and available physical or economic science, enabling business leaders to measure, monitor and manage their climate risks and opportunities.

Developer of a Saas-based cybersecurity software intended to manage security compliance. The company’s software permits building a compliant against insider threat program, track training, manage reporting requirements and prepare for inspections, enabling security managers at federal contractors to stay compliant with NISPOM regulations.

Owner and operator of a sensor development and data management company intended to provide report on vehicular tire tread-wear in real time. The company’s sensors are wireless utilizes sensor technology using carbon nano-tubes and can signal to replace tires or report information about uneven and often dangerous tire wear conditions, enabling users to maintain and keep a track of wear and tear of their automobile tires.

Agtech Accelerator – Vindara, Inc.

Addressing the strategic ATA technology scouting pillar “Novel Farming Systems”, Vindara seeks to address the breeding and biotechnology gap in the vertical farming market. Combining IP enabled genetics into commercialized form factors leverages ATA’s expertise in plant science while capturing the largest value within the food supply chain.

Operator of a health supplements company intended to offer natural supplements for various diseases. The company’s supplements are made from all natural ingredients such as lutein, melatonin, bacopa, allicin, vitex and garlic and it also provides health information to users, enabling individuals to intake organic supplements and recover diseases.